Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Metastatic Testicular Tumors |
Dose: Intravenous – 20 mg/m²/day Frequency: daily Duration: for 5 days per cycle Note: Pretreatment hydration: 1-2 L fluid infused for 8-12 hours before dose. May use concomitant amifostine to decrease nephrotoxicity. Do not repeat course until Serum Creatinine less than 1.5 mg/dL \[less than 133 micromoles/L\] or Blood Urea Nitrogen less than 25 mg/dL \[less than 8.93 mmol/L\] or White Blood Cell count greater than 4000/mm³ AND platelets greater than 100 k/mm³. |
|
Indication: Advanced Bladder Cancer Condition: Initial dose for heavily pretreated patients |
Dose: Intravenous – 50 mg/m²/cycle Frequency: every 4 weeks Note: Pretreatment hydration: 1-2 L fluid infused for 8-12 hours before dose. May use concomitant amifostine to decrease nephrotoxicity. Do not repeat course until Serum Creatinine less than 1.5 mg/dL \[less than 133 micromoles/L\] or Blood Urea Nitrogen less than 25 mg/dL \[less than 8.93 mmol/L\] or White Blood Cell count greater than 4000/mm³ AND platelets greater than 100 k/mm³. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: Tablet – No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment with Creatinine Clearance 10-50 mL/minute |
Dose: Not specified – Decrease dose by 25% Note: Renal Impairment |
|
Condition: Renal Impairment with Creatinine Clearance less than 10 mL/minute |
Dose: Not specified – Administer 50% of dose Note: Renal Impairment |
Administration
- For hospital use only
- Given by IV infusion
Side Effect
- Nausea (76-100%)
- Vomiting (76-100%)
- Nephrotoxicity (28-36%)
- Ototoxicity
- especially in children (31%)
- Myelosuppression (25-30%)
- Anaphylaxis (1-20%)
- Alopecia
- Cerebral herniation
- Encephalopathy
- Leukoencephalopathy and reversible posterior leukoencephalopathy syndrome
- Seizure
- Peripheral neuropathy (dose and duration dependent)
- Diarrhea
- Electrolyte changes
- Hyperuricemia
- Hepatotoxicity
- Local tissue irritation
- Rarely
- renal damage due to inadequate hydration during therapy
- Very rarely life-threatening myelosuppression
- Anaphylactoid reactions (rare) and cardiac abnormalities
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
5-fluorouracil, Etoposide
|
Synergistic effect
|
|
WR 2721 (radioprotecting agent)
|
Increased efficacy and reduced toxicity
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe Renal Disease
|
Can cause irreversible kidney damage
|
|
Auditory Disorder
|
Can cause permanent hearing loss
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Product should be stored at controlled room temperature 25° C and protected from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.